Adicet bio announces positive preliminary data from adi-001 phase 1 study in patients with lupus nephritis (ln) and systemic lupus erythematosus (sle)

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced initial safety and efficacy data from the first seven patients dosed with adi-001 in the ongoing phase 1 study evaluating adi-001 as a potential treatment for patients with autoimmune diseases. the data cut as of august 31, 2025, includes seven patients (five.
ACET Ratings Summary
ACET Quant Ranking